1257. Antiretroviral treatment failure in a prospective cohort of Persons Living with HIV in the Philippines

Abstract Background Widespread access to antiretrovirals has resulted in improved survival among PLHIV resource-limited settings. In a previous study, ART failure the Philippines after one year was found be 10.3%. However, this done as cross-sectional study and did not capture dropouts or pre-existing drug resistance (PDR). Treatment failure, taking into account PDR, dropouts, long-term viral suppression been studied. As part of transmitted (TDR) we prospectively followed patients documented suppression. Methods We enrolled 227 treatment-naïve without TDR on Sanger-based sequencing measured load (VL) every 6 months. VL “>”1000 copies/mL initiation treatment considered failure. An intention treat analysis counting loss follow-up performed along with secondary by subtype. Results at different time points are shown Table 1. Of patients, 177 were subtype CRF01_AE, 30 B, 14 CRF01_AE/B recombinants, 2 CRF02_AG, CRF01_AE/B/F recombinants an A1/D recombinant. Median 295,000 baseline (range: 40 - 658,000 copies/mL). Seventeen developed over observation up 60 months, while 74 lost follow-up. Comparison between B non-B subtypes showed higher rate (OR 2.868 95% CI 1.018 10.016 p=0.0380) year, but no longer significant 24 months (p=0.1534) 48 (p=0.0716). Conclusion HIV is 65.6% analysis. It 63.4% 60.8% Excluding 95.5%, 92.3%, 89.0% 12, 24, respectively. Non-B more likely fail than those first treatment. Loss problem needs addressed proactively order improve local efforts reach 90-90-90 thresholds UNAIDS for control country. Disclosures Edsel Maurice Salvana, MD, MSD: Advisor/Consultant|MSD: Honoraria|Pfizer: Advisor/Consultant|Pfizer: Honoraria.